SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. The brokerage presently has a $1.00 price objective on the stock. Zacks Investment Research‘s price target suggests a potential upside of 1.21% from the stock’s current price.

According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “

SINO BIOPHARMACEUT HKD0.025 (NASDAQ SBMFF) traded up 0.000% on Thursday, hitting $0.988. The stock had a trading volume of 26,000 shares. The company’s 50 day moving average is $0.90 and its 200-day moving average is $0.83. SINO BIOPHARMACEUT HKD0.025 has a 12 month low of $0.64 and a 12 month high of $0.99. The stock has a market cap of $7.32 billion and a P/E ratio of 25.333.

COPYRIGHT VIOLATION NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/16/sino-biopharmaceut-hkd0-025-sbmff-upgraded-to-buy-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on SINO BIOPHARMACEUT HKD0.025 (SBMFF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SINO BIOPHARMACEUT HKD0.025 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SINO BIOPHARMACEUT HKD0.025 and related companies with MarketBeat.com's FREE daily email newsletter.